<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05054543</url>
  </required_header>
  <id_info>
    <org_study_id>APL-106-02</org_study_id>
    <nct_id>NCT05054543</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML</brief_title>
  <official_title>A Phase 3 Randomized, Double-Blinded Bridging Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Chinese Patients With Relapsed/Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apollomics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhejiang CrownMab Biotech Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Apollomics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This bridging study will evaluate the efficacy of uproleselan, a specific E-selectin&#xD;
      antagonist, in combination with chemotherapy to treat Chinese relapsed/refractory AML&#xD;
      patients, compared to chemotherapy alone. The safety of uproleselan when given with&#xD;
      chemotherapy will also be investigated in patients with relapsed/refractory AML&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will enroll approximately 140 randomized subjects 18 through 75 years of age at&#xD;
      the time of randomization with primary refractory AML or relapsed AML (first or second&#xD;
      untreated relapse) and eligible to receive induction chemotherapy as described.&#xD;
&#xD;
      Randomization will be done at trial entry at a 1:1 ratio, and will be stratified by age (&lt;60,&#xD;
      ≥60 years) and disease status (primary refractory/early relapse ≤6 months, late relapse&gt;6&#xD;
      months) and prior HSCT status. Treatment assignment received at randomization will be&#xD;
      maintained during all induction and consolidation cycles.&#xD;
&#xD;
      This trial will have the following sequential phases: screening, baseline, induction&#xD;
      treatment and count recovery, response assessment, consolidation treatment (if remission is&#xD;
      achieved), and follow-up for relapse and survival assessment. Subjects not achieving&#xD;
      remission will continue to be followed for long-term trial endpoints such as disease&#xD;
      progression and survival. Blinding will be maintained until database lock. All subjects will&#xD;
      be followed for long-term outcomes until death or withdrawal of consent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Time from the date of randomization into the study to the date of death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission rate(rate of CR, CR/CRi and CR/CRh)</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Defined as the rate of subjects who reach CR, CR/CRi and CR/CRh</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time from date of first documented remission to date of relapse or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time from date of randomization into the study to the date of treatment failure, relapse, or death from any cause; whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of severe oral mucositis</measure>
    <time_frame>Up to 254 days</time_frame>
    <description>Incidence of severe oral mucositis experienced in patients after treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Relapsed/Refractory AML</condition>
  <arm_group>
    <arm_group_label>Uproleselan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC) during induction; Uproleselan in combination with HiDAC/IDAC during consolidation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Saline, 0.9% Sodium Chloride)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in combination with mitoxantrone, etoposide and cytarabine (MEC) during induction; Placebo in combination with HiDAC/IDAC during consolidation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Uproleselan</intervention_name>
    <description>A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin</description>
    <arm_group_label>Uproleselan</arm_group_label>
    <other_name>GMI-1271</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% Sodium Chloride</description>
    <arm_group_label>Placebo (Saline, 0.9% Sodium Chloride)</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥18 years and ≤75 years in age&#xD;
&#xD;
          2. AML diagnosed with ≥20% myeloid marrow blasts or peripheral blood blasts per WHO&#xD;
             criteria(2008) at the time of initial diagnosis&#xD;
&#xD;
          3. For refractory AML, only cytarabine/daunorubicin(or Idarubicin) as can be applied&#xD;
             repeatedly(maximal twice) as induction, no other chemotherapy are allowed to be&#xD;
             applied Venatoclax /hypomethylation drug [HMA] can be used before and after&#xD;
             chemotherapy.&#xD;
&#xD;
               1. For relapse AML, it must be the first or second relapse, and remain untreated.&#xD;
&#xD;
               2. Certain regimens (Venatoclax/HMA, Venetoclax/LDAC, HMA single agent) and FLT3&#xD;
                  inhibitors, tyrosine kinase inhibitors, IDH1/IDH2 inhibitors or similar targeted&#xD;
                  inhibitors used alone are not considered cytotoxic chemotherapy are allowed.&#xD;
&#xD;
          4. No more than one prior stem cell transplant&#xD;
&#xD;
          5. Has not received the chemotherapy regimen to be used for induction on this trial&#xD;
&#xD;
          6. Is considered medically eligible to receive the chemotherapy regimen to be used for&#xD;
             induction on this trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with acute promyelocytic leukemia&#xD;
&#xD;
          2. Acute leukemia of ambiguous lineage (biphenotypic leukemia)&#xD;
&#xD;
          3. Chronic myeloid leukemia with myeloid blast crisis&#xD;
&#xD;
          4. Active signs or symptoms of CNS involvement by malignancy (No lumbar puncture&#xD;
             required)&#xD;
&#xD;
          5. Prior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing.&#xD;
&#xD;
          6. Stem cell transplantation ≤4 months prior to dosing.&#xD;
&#xD;
          7. Any immunotherapy or radiotherapy therapy within 28 days of dosing; any other&#xD;
             experimental therapy or chemotherapy within 14 days of dosing&#xD;
&#xD;
          8. Inadequate organ function.&#xD;
&#xD;
          9. Abnormal liver function.&#xD;
&#xD;
         10. Known active infection with hepatitis A, B, or C, or human immunodeficiency virus.&#xD;
&#xD;
         11. Moderate kidney dysfunction (glomerular filtration rate &lt;45 mL/min).&#xD;
&#xD;
         12. Uncontrolled acute life-threatening bacterial, viral, or fungal infection.&#xD;
&#xD;
         13. Clinically significant cardiovascular disease.&#xD;
&#xD;
         14. Major surgery within 4 weeks of dosing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianxiang Wang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Hematology and Blood Diseases Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhejiang CrownMab Ltd.</last_name>
    <phone>0571-83521933</phone>
    <email>ClinicalTrialsChina@apollomicsinc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qian Li</last_name>
    <phone>0571-83521933</phone>
    <email>Qian.Li@apollomicsinc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianxiang Wang, Phd</last_name>
      <phone>022-23909120</phone>
      <email>wangjx@medmail.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jie Jin, PhD</last_name>
      <phone>057187236685</phone>
      <email>jiej0503@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

